Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus

被引:9
|
作者
Zervides, Kristoffer A. [1 ,2 ]
Janelidze, Shorena [3 ]
Nystedt, Jessika [2 ]
Gullstrand, Birgitta [1 ]
Nilsson, Petra [2 ]
Sundgren, Pia C. C. [4 ,5 ]
Bengtsson, Anders A. A. [1 ]
Hansson, Oskar [3 ,6 ]
Jonsen, Andreas [1 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Rheumatol, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Neurol, Lund, Sweden
[3] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Malmo, Sweden
[4] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Diagnost Radiol, Lund, Sweden
[5] Lund Univ, BioImaging Ctr, Lund, Sweden
[6] Skane Univ Hosp, Memory Clin, Malmo, Sweden
基金
瑞典研究理事会;
关键词
Neurofilament light; Systemic lupus erythematosus; Neuropsychiatric; Biomarker; Plasma; Cerebrospinal fluid; MRI; Cognitive dysfunction; Organ damage; INDEX; POPULATION; VALIDATION; COMPLEMENT; VALIDITY; CRITERIA;
D O I
10.1186/s12883-022-02998-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundNeuronal damage in systemic lupus erythematosus (SLE) is common, but the extent and mechanisms are unclear. Neurofilament light (NfL) concentrations rise in plasma and cerebrospinal fluid (CSF) during neuronal damage in various neurological disorders. In this cross-sectional study, plasma and CSF concentrations of NfL were explored as a marker of neuronal damage in SLE.MethodsSeventy-two consecutive SLE out-patients and 26 healthy controls, all female, aged < 55 years, underwent magnetic resonance imaging (MRI) and neurocognitive testing. NfL concentrations in plasma from all individuals and in CSF from 32 patients were measured with single-molecule array technology. Patients were assessed by a rheumatologist and neurologist to define neuropsychiatric involvement (NPSLE) according to three attribution models: SLICC A, SLICC B and ACR.ResultsPlasma and CSF NfL concentrations correlated strongly (r = 0.72, p < 0.001). Both NPSLE and non-NPSLE patients in all attribution models had higher plasma NfL concentrations compared with healthy controls (log-NfL, pg/ml, mean (SD); healthy controls (0.71 (0.17)); SLICC A model: NPSLE (0.87 (0.13), p = 0.003), non-NPSLE (0.83 (0.18), p = 0.005); SLICC B model: NPSLE (0.87 (0.14), p = 0.001), non-NPSLE (0.83 (0.18), p = 0.008); ACR model: NPSLE (0.86 (0.16), p < 0.001), non-NPSLE (0.81 (0.17), p = 0.044)). Plasma and CSF NfL concentrations did not differ between NPSLE and non-NPSLE patients. Higher plasma NfL concentrations correlated with larger CSF volumes on MRI (r = 0.34, p = 0.005), and was associated with poorer cognitive performance in the domains of simple attention, psychomotor speed and verbal memory. SLICC/ACR-Damage Index >= 1 was independently associated with higher plasma NfL concentrations (beta = 0.074, p = 0.038). Higher plasma creatinine concentrations, anti-dsDNA-positivity, low complement C3 levels, or a history of renal involvement were associated with higher plasma NfL concentrations (beta = 0.003, p = 0.009; beta = 0.072, p = 0.031; beta = 0.077, p = 0.027; beta = 0.069, p = 0.047, respectively).ConclusionsHigher plasma NfL concentrations in NPSLE and non-NPSLE patients may indicate a higher degree of neuronal damage in SLE in general, corresponding to cognitive impairment and organ damage development. Furthermore, our results may indicate a higher degree of neuronal breakdown in patients with active SLE, also without overt clinical symptoms. NfL may serve as an indicator of neuronal damage in SLE in further studies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Predictors of Damage Progression in Portuguese Patients with Systemic Lupus Erythematosus
    Santos, Maria Jose
    Vinagre, Filipe
    Nero, Patricia
    Barcelos, Filipe
    Barcelos, Anabela
    Rodrigues, Ana Maria
    de Matos, Antonio Alves
    Silva, Candida
    Miranda, Luis
    Capela, Susana
    Marques, Aurora
    Branco, Jaime
    da Silva, Jose Canas
    CONTEMPORARY CHALLENGES IN AUTOIMMUNITY, 2009, 1173 : 822 - 828
  • [32] Utility of osteopontin in cerebrospinal fluid as a diagnostic marker for neuropsychiatric systemic lupus erythematosus
    Kitagori, K.
    Yoshifuji, H.
    Oku, T.
    Ayaki, T.
    Kuzuya, A.
    Nakajima, T.
    Akizuki, S.
    Nakashima, R.
    Murakami, K.
    Ohmura, K.
    Hirayama, Y.
    Takahashi, R.
    Mimori, T.
    LUPUS, 2019, 28 (03) : 414 - 422
  • [33] Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease
    Kanata, Eirini
    Golanska, Ewa
    Villar-Pique, Anna
    Karsanidou, Aikaterini
    Dafou, Dimitra
    Xanthopoulos, Konstantinos
    Schmitz, Matthias
    Ferrer, Isidro
    Karch, Andre
    Sikorska, Beata
    Liberski, Pawel P.
    Sklaviadis, Theodoros
    Zerr, Inga
    Llorens, Franc
    JOURNAL OF CLINICAL NEUROSCIENCE, 2019, 60 : 124 - 127
  • [34] To What Extent Can Preventive Treatments Prevent Damage From Systemic Lupus Erythematosus?
    Massarotti, Elena M.
    Schur, Peter H.
    CURRENT RHEUMATOLOGY REPORTS, 2011, 13 (04) : 317 - 323
  • [35] Higher Levels of Cerebrospinal Fluid and Plasma Neurofilament Light in Human Immunodeficiency Virus-associated Distal Sensory Polyneuropathy
    Ellis, Ronald J.
    Chenna, Ahmed
    Lie, Yolanda
    Curanovic, Dusica
    Winslow, John
    Tang, Bin
    Marra, Christina M.
    Rubin, Leah H.
    Clifford, David B.
    McCutchan, J. Allen
    Gelman, Benjamin B.
    Robinson-Papp, Jessica
    Petropoulos, Christos J.
    Letendre, Scott L.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (06) : 1103 - 1109
  • [36] Serial cerebrospinal fluid neurofilament concentrations in bacterial meningitis
    Matsushige, Takeshi
    Ichiyama, Takashi
    Kajimoto, Madoka
    Okuda, Masayuki
    Fukunaga, Shinnosuke
    Furukawa, Susumu
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 280 (1-2) : 59 - 61
  • [37] MARKED CEREBROSPINAL-FLUID PLEOCYTOSIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS RELATED CEREBRAL-ISCHEMIA
    ABIALMOUNA, J
    SHOEMAKER, DW
    PULLICINO, PM
    BAER, AN
    JOURNAL OF RHEUMATOLOGY, 1992, 19 (04) : 626 - 629
  • [38] Systemic Lupus Erythematosus With Isolated Psychiatric Symptoms and Antinuclear Antibody Detection in the Cerebrospinal Fluid
    Luengen, Eva M.
    Maier, Viktoria
    Venhoff, Nils
    Salzer, Ulrich
    Dersch, Rick
    Berger, Benjamin
    Riering, Anne N.
    Nickel, Kathrin
    Fiebich, Bernd L.
    Suess, Patrick
    Maier, Simon J.
    Egger, Karl
    van Elst, Ludger Tebartz
    Endres, Dominique
    FRONTIERS IN PSYCHIATRY, 2019, 10
  • [39] Correlation between irreversible organ damage and the quality of life of patients with systemic lupus erythematosus: The Kyoto Lupus Cohort survey
    Takase, Yudai
    Iwasaki, Takeshi
    Doi, Hiroshi
    Tsuji, Hideaki
    Hashimoto, Motomu
    Ueno, Kentaro
    Inaba, Ryuta
    Kozuki, Tomohiro
    Taniguchi, Masashi
    Tabuchi, Yuya
    Watanabe, Ryu
    Kitagori, Koji
    Akizuki, Shuji
    Murakami, Kosaku
    Nakashima, Ran
    Yoshifuji, Hajime
    Itaya, Takahiro
    Yamamoto, Wataru
    Uozumi, Ryuji
    Tanaka, Masao
    Ohmura, Koichiro
    Morinobu, Akio
    LUPUS, 2021, 30 (10) : 1577 - 1585
  • [40] Plasma C4d as marker for lupus nephritis in systemic lupus erythematosus
    Martin, Myriam
    Smolag, Karolina I.
    Bjork, Albin
    Gullstrand, Birgitta
    Okroj, Marcin
    Leffler, Jonatan
    Jonsen, Andreas
    Bengtsson, Anders A.
    Blom, Anna M.
    ARTHRITIS RESEARCH & THERAPY, 2017, 19